|
|
Article: NeoPharm's Cintredekin Besudotox Well-Tolerated in Newly Diagnosed Malignant Glioma Patients.
- Article from:
- Business Wire
- Article date:
- April 25, 2006
CopyrightCOPYRIGHT 2006 Business Wire. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
SAN FRANCISCO -- NeoPharm, Inc. (Nasdaq:NEOL):
--Phase I Study Confirms Combination Therapy that Includes Cintredekin Besudotox May Be An Option For This Patient Population
NeoPharm, Inc. (Nasdaq:NEOL) today announced that, based upon a recent Phase I study, evidence was provided that cintredekin besudotox (IL13-PE38QQR) appears to be safe and well tolerated in newly diagnosed malignant glioma patients. Results from the Phase I study will be presented at the 74th Annual Meeting of the American Association of Neurological Surgeons (AANS) held in San Francisco on Tuesday, April 25, 2006
"We always try to optimize the safety and efficacy of ...